# HUTCHMED (China) Limited (HCM)

> Source: Nexqual · https://nexqual.com/HCM · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, HUTCHMED (China) Limited (HCM), nexqual.com/HCM" · informational, not investment advice.

**Price:** USD 14.28 (-0.63% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 14.37 · day 14.22–14.36 · 52w 9.77–16.33 · market cap $2.48B · NMS

## Key facts
- Analysts: Buy (mean 2.08 on a 1–5 scale) (12 analysts), mean target USD 20.59 (range 13.6–33.27).
- Total return with dividends: 1Y -5.0% vs S&P 500 +14.9%; 5Y -55.6% vs S&P 500 +80.3%.
- Next earnings: 2026-07-30, EPS estimate USD —, revenue estimate $0K.

## Analysts
Consensus Buy (mean 2.08 on a 1–5 scale), 12 analysts; mean target USD 20.59 (low 13.6, high 33.27).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-23 | Goldman Sachs | Target lowered | Neutral | $16 → $14 |
| 2026-07-07 | B of A Securities | Target lowered | Buy | $20 → $17 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -5.0% | -55.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -5.1% | -15.0% |
| Volatility (annualized) | 38.1% | 59.5% |
| Max drawdown | -37.8% (Jan 2026→Jun 2026) | -77.4% (Dec 2021→Oct 2022) |

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 42.07 +2.09% · BHC (Bausch Health Companies Inc.) USD 6.49 +0.62% · LQDA (Liquidia Corporation) USD 39.69 +2.14% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 28.57 -1.58% · INDV (Indivior Pharmaceuticals, Inc.) USD 35.33 +1.55% · RGC (Regencell Bioscience Holdings L) USD 9.81 -9.17%

## More
Full page: https://nexqual.com/HCM · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in HCM's own 20-F filed 2026-03-05 (https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Shanghai Hutchison Pharmaceuticals | "Revenue from our Other Ventures also comprises revenue from sales of Zhi Ling Tong infant nutrition and other health supplement products manufactured by Hutchison Healthcare and distributed through Shanghai Hutchison Pha…" |
| Partner | Eli Lilly (LLY) | "We and our collaboration partners, including AstraZeneca, Eli Lilly, Takeda, ImageneBio, Miragene, Innovent, and Epizyme, Inc. (a subsidiary of Ipsen Pharma SAS, "Epizyme") may experience delays in completing our pre-cli…" |
| Partner | Group and Takeda Pharmaceuticals International | "Our collaborations, including those with our oncology drug partners AstraZeneca, Eli Lilly and Takeda and our in-licensing arrangement with Epizyme, and any future collaborations that we enter into may not be successful." |
| Partner | Epizyme | "Our collaborations, including those with our oncology drug partners AstraZeneca, Eli Lilly and Takeda and our in-licensing arrangement with Epizyme, and any future collaborations that we enter into may not be successful." |
| Partner | Hutchison Whampoa Enterprises | "The Brand License Agreement contains provisions on quality control pursuant to which we are obliged to use the brands and related materials in compliance with the brand guidelines, industry best practice and other qualit…" |
| Partner | ImageneBio, Inc. (IMA) | "We and our collaboration partners, including AstraZeneca, Eli Lilly, Takeda, ImageneBio, Miragene, Innovent, and Epizyme, Inc. (a subsidiary of Ipsen Pharma SAS, "Epizyme") may experience delays in completing our pre-cli…" |
| Partner | Jiangsu Hengrui Pharmaceuticals | "In 2024, we entered into a collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") to evaluate the combination of Sulanda, the Hengrui PD-1 antibody camrelizumab, nab-paclitaxel and gemcitabine as a first…" |
| Partner | Luye Pharma Hong Kong | "The terms of our agreement with AstraZeneca were assigned to Luye Pharma Hong Kong Ltd., or Luye Pharma HK." |
| Partner | Hutchison Whampoa | "The Services Agreement replaces our prior services agreement with Hutchison Whampoa (China) Limited, dated April 21, 2006, which had substantially similar terms." |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2026-12-31) | $0.22 | $0.36 | -37.5% | $626.6M | 6 |
| Next fiscal year (ends 2027-12-31) | $0.26 | $0.49 | -47.5% | $698.8M | 6 |

## Options: expected move (Cboe, 15-min delayed)

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 132.8% | ±9.8% |
| 2027-02-19 | 119 | 75.2% | ±37.1% |